Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment

References

• EastellRTreatment of postmenopausal osteoporosisN Engl J Med1998338117367469494151
   PubMed Web of Science ®Google Scholar
• GuyattGHCranneyAGriffithLSummary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fracturesEndocrinol Metab Clin North Am200231365967912227126
   PubMed Web of Science ®Google Scholar
• BlackDMThompsonDEThe effect of alendronate therapy on osteoporotic fracture in the vertebral fracture arm of the Fracture Intervention TrialInt J Clin Pract Suppl1999101465012669740
   PubMedGoogle Scholar
• ChesnutCHSkagAChristiansenCEffects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosisJ Bone Miner Res20041981241124915231010
   PubMed Web of Science ®Google Scholar
• HarrisSTWattsNBGenantHKEffects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study GroupJAMA1999282141344135210527181
   PubMed Web of Science ®Google Scholar
• McClungMRBisphosphonates in osteoporosis: recent clinical experienceExpert Opin Pharmacother20001222523811249544
   PubMedGoogle Scholar
• ChesnutCHTreating osteoporosis with bisphosphonates and addressing adherence: a review of oral ibandronateDrugs200666101351135916903769
   PubMed Web of Science ®Google Scholar
• GoldDTMartinBCFrytakJRAmonkarMMCosmanFA claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosisCurr Med Res Opin200723358559417355739
   PubMed Web of Science ®Google Scholar
• SirisESHarrisSTRosenCJAdherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databasesMayo Clin Proc20068181013102216901023
   PubMed Web of Science ®Google Scholar
• van den BoogaardCHBreekveldt-PostmaNSBorggreveSEGoettschWGHeringsRMPersistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: A database analysis studyCurr Med Res Opin20062291757176416968579
   PubMed Web of Science ®Google Scholar
• EttingerBPressmanAScheinJChanJSilverPConnollyNAlendronate use among 812 women: prevelance of gastrointestinal complaints, noncompliance with patient instructions, and discontinuationJ Manag Care Pharm199845488492
   Google Scholar
• HamiltonBMcCoyKTaggartHTolerability and compliance with risedronate in clinical practiceOsteoporosis Int200314256262
   Web of Science ®Google Scholar
• Penning-van BeestFJGoettschWGErkensJAHeringsRMDeterminants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosisClin Ther200628223624216678644
   PubMed Web of Science ®Google Scholar
• LanzaFLGastrointestinal adverse effects of bisphosphonates: etiology, incidence and preventionTreat Endocrinol200211374315765619
   PubMedGoogle Scholar
• LichtenbergerLMRomeroJJGibsonGWBlankMAEffect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosaDig Dis Sci20004591792180111052322
   PubMed Web of Science ®Google Scholar
• CryerBBauerDCOral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?Mayo Clin Proc200277101031104312374247
   PubMed Web of Science ®Google Scholar
• BlumentalsWAHarrisSTColeREHuangLSilvermanSLRisk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronateAnn Pharmacother200943457758519318598
   PubMed Web of Science ®Google Scholar
• BlackDMThompsonDEBauerDCFracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research GroupJ Clin Endocrinol Metab200085114118412411095442
   PubMed Web of Science ®Google Scholar
• EismanJARizzoliRRoman-IvorraJUpper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled studyCurr Med Res Opin200420569970515140336
   PubMed Web of Science ®Google Scholar
• PolsHAFelsenbergDHanleyDAMultinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study GroupOsteoporos Int19999546146810550467
   PubMed Web of Science ®Google Scholar
• ReginsterJMinneHWSorensenOHRandomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study GroupOsteoporos Int2000111839110663363
   PubMed Web of Science ®Google Scholar
• LanzaFLHuntRHThomsonABProvenzaJMBlankMAEndoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal womenGastroenterology2000119363163810982755
   PubMed Web of Science ®Google Scholar
• Boniva (ibandronate sodium) injection US prescribing informationNutley, NJRoche Laboratories Inc2007
   Google Scholar
• Boniva (ibandronate sodium) US prescribing informationNutley, NJRoche Laboratories Inc2008
   Google Scholar
• LewieckiEMBabbittAMPiziakVKOzturkZEBoneHGAdherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluationClin Ther200830460562118498910
   PubMed Web of Science ®Google Scholar
• BonnickSLSilvermanSLTannerSBPatient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronateJ Womens Health2009187935943
   Web of Science ®Google Scholar
• FloodEMBeusterienKMGreenHPsychometric evaluation of the Osteoporosis Patient Treatment Satisfaction Questionnaire (OPSAT-Q), a novel measure to assess satisfaction with bisphosphonate treatment in postmenopausal womenHealth Qual Life Outcomes200644216834773
   PubMed Web of Science ®Google Scholar
• BinkleyNMartensMGSilvermanSLImproved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonatesSouth Med J2009102548649219373149
   PubMed Web of Science ®Google Scholar
• de GroenPCLubbeDFHirschLJEsophagitis associated with the use of alendronateN Engl J Med199633514101610218793925
   PubMed Web of Science ®Google Scholar
• EttingerBPressmanAScheinJClinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosisAm J Manage Care199841013771382
   PubMed Web of Science ®Google Scholar
• SuriSMonkkonenJTaskinenMNitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicityBone200129433634311595616
   PubMed Web of Science ®Google Scholar
• WallaceJLDicayMMcKnightWBastakiSBlankMAN-bisphosphonates cause gastric epithelial injury independent of effects on the microcirculationAliment Pharmacol Ther199913121675168210594404
   PubMed Web of Science ®Google Scholar
• MillerRGBologneseMWorleyKSolisASheerRIncidence of gastrointestinal events among bisphosphonate patients in an observational settingAm J Manag Care2004107S207215
   Web of Science ®Google Scholar
• BlackDMCummingsSRKarpfDBRandomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research GroupLancet19963489041153515418950879
   PubMed Web of Science ®Google Scholar
• McClungMRGeusensPMillerPDEffect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study GroupN Engl J Med2001344533334011172164
   PubMed Web of Science ®Google Scholar
• ChesnutCHEttingerMPMillerPDIbandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONECurr Med Res Opin200521339140115811208
   PubMed Web of Science ®Google Scholar
• BrownJPKendlerDLMcClungMRThe efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosisCalcif Tissue Int200271210311112085156
   PubMed Web of Science ®Google Scholar
• DelmasPDMcClungMRZanchettaJREfficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosisBone2008421364217920005
   PubMed Web of Science ®Google Scholar
• SchnitzerTBoneHGCrepaldiGTherapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-weekly Study GroupAging (Milano)20021211210746426
   PubMedGoogle Scholar
• ReginsterJYAdamiSLakatosPEfficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE studyAnn Rheum Dis20066565465116339289
   PubMed Web of Science ®Google Scholar
• CranneyAWellsGAYetisirEIbandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient dataOsteoporos Int200920229129718663402
   PubMed Web of Science ®Google Scholar
• HarrisSTBlumentalsWAMillerPDIbandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studiesCurr Med Res Opin200824123724518047776
   PubMed Web of Science ®Google Scholar
• HarrisSTReginsterJYHarleyCRisk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: The eValuation of IBandronate Efficacy (VIBE) database fracture studyBone200944575876519168160
   PubMed Web of Science ®Google Scholar